Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01604512 : A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Pathological or clinical/radiological diagnosis of aneoplasm , either primary (e.g.,
malignant glioma) or secondary (metastasis from systemic malignancy) with a history of
brain radiation therapy

- Completed fractionated radiation therapy (to 60 Gy for high grade gliomas) or
stereotactic radiosurgery or hypofractionated radiation therapy (e.g. for brain
metastases, anaplastic meningiomas), without or with concurrent chemotherapy

- New or increased enhancing brain lesion(s) OR nonenhancing brain lesion(s) if
receiving anti-angiogenic therapy, which is considered indeterminate for tumor
progression vs. radiation injury by the neuroradiologist or clinician

- Patient and/or guardian is able to provide written informed consent prior to study

- Age = 18 years old

Exclusion Criteria:

- Claustrophobia

- Known allergic reaction to Gd-DTPA

- Any contraindication to gadolinium intravenous contrast as per standard Department of
Radiology contrast guidelines

- Any contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander).

- Pregnant or nursing female

- Unable to cooperate for MRI and/or PET/CT
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557